“It’s an exciting time in UTUC,” says Joseph Jacob, MD.
In this video, Joseph Jacob, MD, talks about the future of nonsurgical treatment in upper tract urothelial carcinoma. Jacob is an assistant professor of urology at SUNY Upstate Medical University in Syracuse, New York.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.